-
[ICKSH 2025] ‘Ph-like ALL treatment paradigm shifting toward molecularly guided immuno- and targeted therapy’
10 Apr 2025 07:18 GMT
… , titled, “Diagnosis and treatment of Ph-like in children … in both its diagnosis and treatment.
“Ph-like ALL … balancing resources.
On the treatment front, Professor Tran noted … running prospective trials such as AALL1732 (testing blinatumomab plus inotuzumab …
-
New Drug Approvals in China: An International Comparative Analysis, 2019-2023
03 Apr 2025 11:18 GMT
… Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical … therapy, the treatment of genetic … etc. However, blinatumomab and glofitamab are … cancer in China compared to the US, conducting large-scale multicenter trials …
-
Imugene Advances Phase 1 onCARlytics Trial with IV Dose Escalation for Solid Tumours
03 Apr 2025 02:40 GMT
… blinatumomab to induce CD19 expression in solid tumours.
The multi-centre trial … are redefining the boundaries of cancer treatment. Imugene Ltd (ASX:IMU), through … reshape the treatment landscape for patients with high unmet medical needs in …
-
October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
31 Mar 2025 19:52 GMT
… more antidepressant(s)
Discontinuation-emergent cataplexy
FDA is … 47;Hypersensitivity Reactions
Blincyto (blinatumomab) for injection
Columvi …
Cutaneous T-cell lymphoma
FDA is evaluating the … about hepatotoxicity.
An FDA Drug Safety Communication was …
-
Acute Lymphocytic Leukemia Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism Of Action, ROA, NDA, IND, And Companies
27 Mar 2025 04:31 GMT
… ALL)/lymphoblastic lymphoma (LL) and … Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals … drug is in Phase III stage of its development for the treatment … Therapies- Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, …
-
Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too
27 Mar 2025 03:22 GMT
… Medicine by Mark R. Litzow, MD, was on the E1910 trial … B-ALL with trials examining the consolidation … morbidity, [and] cumulative treatment toxicity, they may be … .fda.gov/drugs/;resources-information-approved-drugs/fda-approves-blinatumomab- …
-
Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Blood and lymphatic system…
24 Mar 2025 21:19 GMT
P/0040/2024 : EMA decision of 7 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for blinatumomab, (Blincyto) (EMEA-000574-PIP03-23)
AdoptedReference Number: EMA…
-
Childhood Leukemia Isn't What It Used to Be: Latest Treatments, Research, and Reasons to Hope
21 Mar 2025 04:13 GMT
… Leukemia and Lymphoma Program and … cancerous cells from returning.
Blinatumomab and other immunotherapies: Blinatumomab … accordingly.
Additionally, doctors focus on supporting … treatment has been made through clinical trials,” says Dr. Bhojwani.
CHLA’s Cancer …
-
Amgen’s Blincyto OKed for consolidation therapy in ALL, shifting treatment paradigm
13 Mar 2025 03:43 GMT
… ingredient: blinatumomab) has significantly expanded its role in the treatment of … Ministry of Food and Drug Safety (MFDS) approved … results from the E1910 trial.
This study examined MRD … amp; Oncology at Asan Medical Center highlighted findings from the …
-
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
07 Mar 2025 16:07 GMT
… abnormalities.24 Clinical trials have reported encouraging … research into novel pharmaceuticals and combination therapies … 3390/cancers14143526
Peripheral T-cell non-Hodgkin lymphoma treatment (PDQ)- … salvage therapy with blinatumomab in patients with …
About
© 1995-2025